KRTX
NASDAQKaruna Therapeutics Inc.
Latest news
25 items- PRPureTech Announces Annual Results for Year Ended December 31, 2023Significant operational and clinical progress in 2023 and early 2024 with maturation of Internal Programs,1 launch of two new Founded Entities,2 including a $100 million Series A financing for Seaport, and the $14 billion acquisition of Karuna by Bristol Myers Squibb Robust balance sheet with PureTech level cash, cash equivalents and short-term investments of $326.0 million3 and consolidated cash, cash equivalents and short-term Investments of $327.1 million4 as of December 31, 2023 As of March 31, 2024, PureTech level cash, cash equivalents and short-term investments were $573.3 million,5 enabling the support of Internal Programs and Founded Entities, future innovations, shareholder re
- SECSEC Form 15-12G filed by Karuna Therapeutics Inc.15-12G - Karuna Therapeutics, Inc. (0001771917) (Filer)
- INSIDERHealy James returned $466,830,870 worth of shares to the company (1,414,639 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERPande Atul returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERBrown Jason Parker returned $6,985,110 worth of shares to the company (21,167 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERWheadon David E. returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERJonas Jeffrey M returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDEROlson Laurie J returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERTorres Denice returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERMiller Andrew Craig returned $7,718,370 worth of shares to the company (23,389 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERPaul Steven M returned $49,817,790 worth of shares to the company (150,963 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERMeury William returned $9,695,070 worth of shares to the company (29,379 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERBrannan Stephen K. returned $14,059,320 worth of shares to the company (42,604 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERCoughlin Christopher J returned $326,700 worth of shares to the company (990 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- INSIDERKane William P Jr returned $4,563,240 worth of shares to the company (13,828 units at $330.00), closing all direct ownership in the company (SEC Form 4)4 - Karuna Therapeutics, Inc. (0001771917) (Issuer)
- SECSEC Form S-8 POS filed by Karuna Therapeutics Inc.S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECSEC Form S-8 POS filed by Karuna Therapeutics Inc.S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECSEC Form S-8 POS filed by Karuna Therapeutics Inc.S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECSEC Form S-8 POS filed by Karuna Therapeutics Inc.S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECSEC Form S-8 POS filed by Karuna Therapeutics Inc.S-8 POS - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECSEC Form 25-NSE filed by Karuna Therapeutics Inc.25-NSE - Karuna Therapeutics, Inc. (0001771917) (Subject)
- SECSEC Form POSASR filed by Karuna Therapeutics Inc.POSASR - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECKaruna Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - Karuna Therapeutics, Inc. (0001771917) (Filer)
- SECSEC Form 10-K/A filed by Karuna Therapeutics Inc. (Amendment)10-K/A - Karuna Therapeutics, Inc. (0001771917) (Filer)
- NEWSHC Wainwright & Co. Maintains Neutral on Karuna Therapeutics, Maintains $330 Price TargetHC Wainwright & Co. analyst Raghuram Selvaraju maintains Karuna Therapeutics (NASDAQ:KRTX) with a Neutral and maintains $330 price target.
KRTX FAQ
7 questionsWhat does Karuna Therapeutics Inc. do?
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The...Where does KRTX stock trade?
Karuna Therapeutics Inc. (KRTX) is listed on NASDAQ.What sector and industry is KRTX in?
Karuna Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Karuna Therapeutics Inc. go public?
Karuna Therapeutics Inc. (KRTX) completed its IPO in 2019.What are analysts saying about KRTX?
Karuna Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Citigroup: Buy on 2023-12-12.What companies are similar to KRTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare KRTX side-by-side with any of them on Quantisnow.How can I track KRTX on Quantisnow?
Quantisnow aggregates Karuna Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRTX to receive live email and push alerts on every new disclosure.